170 related articles for article (PubMed ID: 27673440)
1. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Ragon BK; Kantarjian H; Jabbour E; Ravandi F; Cortes J; Borthakur G; DeBose L; Zeng Z; Schneider H; Pemmaraju N; Garcia-Manero G; Kornblau S; Wierda W; Burger J; DiNardo CD; Andreeff M; Konopleva M; Daver N
Am J Hematol; 2017 Jan; 92(1):7-11. PubMed ID: 27673440
[TBL] [Abstract][Full Text] [Related]
2. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
3. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.
Wu YL; Zhang LI; Trandafir L; Dong T; Duval V; Hazell K; Xu B
Anticancer Res; 2016 Nov; 36(11):6185-6194. PubMed ID: 27793950
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Ando Y; Inada-Inoue M; Mitsuma A; Yoshino T; Ohtsu A; Suenaga N; Sato M; Kakizume T; Robson M; Quadt C; Doi T
Cancer Sci; 2014 Mar; 105(3):347-53. PubMed ID: 24405565
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Rodon J; Braña I; Siu LL; De Jonge MJ; Homji N; Mills D; Di Tomaso E; Sarr C; Trandafir L; Massacesi C; Eskens F; Bendell JC
Invest New Drugs; 2014 Aug; 32(4):670-81. PubMed ID: 24652201
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
McRee AJ; Marcom PK; Moore DT; Zamboni WC; Kornblum ZA; Hu Z; Phipps R; Anders CK; Reeder-Hayes K; Carey LA; Weck KE; Perou CM; Dees EC
Clin Breast Cancer; 2018 Aug; 18(4):289-297. PubMed ID: 29153866
[TBL] [Abstract][Full Text] [Related]
8. A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer.
Goodwin R; Jonker D; Chen E; Kennecke H; Cabanero M; Tsao MS; Vickers M; Bohemier C; Lim H; Ritter H; Tu D; Seymour L
Invest New Drugs; 2020 Aug; 38(4):1077-1084. PubMed ID: 31506897
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
[TBL] [Abstract][Full Text] [Related]
10. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Hainsworth JD; Becker KP; Mekhail T; Chowdhary SA; Eakle JF; Wright D; Langdon RM; Yost KJ; Padula GDA; West-Osterfield K; Scarberry M; Shaifer CA; Shastry M; Burris HA; Shih K
J Neurooncol; 2019 Sep; 144(2):303-311. PubMed ID: 31392595
[TBL] [Abstract][Full Text] [Related]
12. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
Younes A; Salles G; Martinelli G; Bociek RG; Barrigon DC; Barca EG; Turgut M; Gerecitano J; Kong O; Pisal CB; Tavorath R; Kim WS
Haematologica; 2017 Dec; 102(12):2104-2112. PubMed ID: 28971900
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Vansteenkiste JF; Canon JL; De Braud F; Grossi F; De Pas T; Gray JE; Su WC; Felip E; Yoshioka H; Gridelli C; Dy GK; Thongprasert S; Reck M; Aimone P; Vidam GA; Roussou P; Wang YA; Di Tomaso E; Soria JC
J Thorac Oncol; 2015 Sep; 10(9):1319-1327. PubMed ID: 26098748
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
15. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Geuna E; Milani A; Martinello R; Aversa C; Valabrega G; Scaltriti M; Montemurro F
Expert Opin Investig Drugs; 2015 Mar; 24(3):421-31. PubMed ID: 25645727
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Heudel PE; Fabbro M; Roemer-Becuwe C; Kaminsky MC; Arnaud A; Joly F; Roche-Forestier S; Meunier J; Foa C; You B; Priou F; Tazi Y; Floquet A; Selle F; Berton-Rigaud D; Lesoin A; Kalbacher E; Lortholary A; Favier L; Treilleux I; Ray-Coquard I
Br J Cancer; 2017 Jan; 116(3):303-309. PubMed ID: 28072765
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
18. Buparlisib in breast cancer.
Sirohi B; Rastogi S; Dawood S
Future Oncol; 2015; 11(10):1463-70. PubMed ID: 25963424
[TBL] [Abstract][Full Text] [Related]
19. Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Borson-Chazot F; Dantony E; Illouz F; Lopez J; Niccoli P; Wassermann J; Do Cao C; Leboulleux S; Klein M; Tabarin A; Eberle MC; Benisvy D; de la Fouchardière C; Bournaud C; Lasolle H; Delahaye A; Rabilloud M; Lapras V; Decaussin-Petrucci M; Schlumberger M
Thyroid; 2018 Sep; 28(9):1174-1179. PubMed ID: 30105951
[TBL] [Abstract][Full Text] [Related]
20. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
Furman WL; Stewart CF; Kirstein M; Kepner JL; Bernstein ML; Kung F; Vietti TJ; Steuber CP; Becton DL; Baruchel S; Pratt C
J Clin Oncol; 2002 Mar; 20(6):1617-24. PubMed ID: 11896112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
